Article about MGMT study accepted for publication in Neoplasma TUE, SEP 25, 2018 08:17 CET A scientific article on Double Bond Pharmaceutical's investigation into how MGMT status affects the effectiveness of treatment with Temodex has been accepted for publication in the journal Neoplasma. "The information [...]
Double Bond Pharmaceutical and NIHR signed an agreement for Study Support WED, SEP 19, 2018 07:58 CET Double Bond Pharmaceutical (DBP) and The National Institute for Health Research (NIHR) in the UK have signed an agreement for support with an investigation of rapid study set-up [...]
Double Bond Pharmaceutical pushes start date of Belopenem project forward to October 1st TUE, SEP 04, 2018 08:11 CET Double Bond Pharmaceuticals Eurostar project Belopenem will start already October 1, 2018 instead of previously announced November 1, 2018. The project is a collaboration with, amongst [...]
In-use stability for SI-053 is ensured FRI, AUG 31, 2018 08:16 CET Double Bond Pharmaceutical reports that a European GMP-certified contract manufacturer has examined the highest dose of the SI-053 formulation, the results show that the formulation is stable over time (8 hours). "Formulation stability [...]
Successful crowd funding by FarmPharma via FundedByMe WED, AUG 29, 2018 08:53 CET On June 20 this year, FarmPharma AB started a crowd funding campaign to bring together funding for the company's further development. Today, 100% of the minimum target has been achieved and more [...]
DBP has signed an agreement of scientific and technical partnership with the Biochemistry cluster of ITMO University THU, AUG 23, 2018 08:00 CET Double Bond Pharmaceutical and the Biochemistry cluster SCAMT of ITMO University (St Petersburg, Russian Federation) have signed an agreement of scientific and [...]
DBP has signed an agreement with Apotek365 for the sale of Pileseptin and HalsEze MON, AUG 20, 2018 08:00 CET Double Bond Pharmaceuticals subsidiary Drugsson and the online pharmacy Apotek365 has signed an agreement to sell HalsEze and Pileseptin. "Another pharmacy shows interest in the [...]
Double Bond Pharmaceutical manufactures first GMP batch of SI053 WED, AUG 15, 2018 08:07 CET Double Bond Pharmaceuticals contract manufacturer of SI053 reports that they have successfully manufactured the first GMP batch. The batch is to be used among other things for the stability study [...]
Double Bond Pharmaceutical receives patent in the United States for the BeloGal® platform TUE, JUL 31, 2018 08:00 CET Double Bond Pharmaceuticals patent application for organ-specific administration of hydrophilic cancer drug to the liver which forms the basis for the BeloGal® technology platform has been [...]
The sterilization process for Temozolomide is secured MON, JUL 23, 2018 08:00 CET Double Bond Pharmaceutical reports that technology transfer of the sterilization process for Temozolomide in SI-053 has been conducted with satisfactory results. The process has been carried out by a company specializing in [...]